Alzheimer's Disease

'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update
Cannabis-Based Dronabinol Could Transform Alzheimer's Care, New Study Finds
Shark Tank's Barbara Corcoran Reveals Her Struggle With Alzheimer's In Her Family
Cannabis-Based Dronabinol Could Transform Alzheimer's Care, New Study Finds
Shark Tank's Barbara Corcoran Reveals Her Struggle With Alzheimer's In Her Family
This Medical Stock Soared Over 80% In Pre-Market After Advancing Gene Therapy Program For ALS, Alzheimer's And Parkinson's Diseases
Eli Lilly Shares Gain After Drug-Maker Gets FDA's Nod For Early Alzheimer's Treatment

Alzheimer's Disease Recent News

Could CBD Revolutionize Alzheimer's Treatment? New Study Explores Its Neuroprotective Properties
Cannabidiol (CBD), a non-psychoactive compound found in the cannabis plant, has emerged as a potential therapeutic agent for Alzheimer's Disease. While research is still in the early stages, several studies have shown that CBD may help prevent and alleviate some of the disease’s symptoms. 
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this 
Autism Therapy: Cannformatics Targets Metabolic Imbalances Using Machine Learning
Cannformatics, an early-stage biotechnology company, has unveiled a groundbreaking advancement in the field of medical cannabis treatment for Autism Spectrum Disorder (ASD).
FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline
The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval.
Exclusive: FloraWorks Completes $2.25M Series-A Financing For Cannabinoid Research
FloraWorks, a cannabinoid therapeutics company specializing in rare and novel cannabinoids, has successfully completed a $2.25 million Series-A financing round. Leading this significant investment was life sciences venture capital firm, Bonaventure Equity LLC.
Roche's Another Alzheimer's Hopeful Flops In Phase 3 Program, Second Trial Setback Within Months
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock
Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate.
EXCLUSIVE: Cognition Therapeutics Shares Biomarker Data From Alzheimer's Candidate
Cognition Therapeutics Inc (NASDAQ: CGTX) presented a proteomic analysis of clinical biomarker data from the SPARC study of CT1812 in mild-to-moderate Alzheimer's disease at the Alzheimer's Association International Conference. 
Researchers Investigate New Treatment Pathways For Alzheimer's After Commercial Failure Of Biogen's Aduhelm
The commercial failure of Biogen Inc's (NASDAQ: BIIB) drug Aduhelm has put a new focus on the research into the causes of Alzheimer's disease.
Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug
New York Times Report Fresh Allegations On Cassava's Simufilam Alzheimer's Trials, Shares Fall
Cassava Sciences Inc (NASDAQ: SAVA) shares are shedding over 20% after 
Biogen's Alzheimer's Drug Aduhelm Medicare Coverage Restricted To Just Clinical Trials, CMS Finalizes
Centers for Medicare and Medicaid Services (CMS) finalized its decision to restrict coverage for Biogen Inc's (NASDAQ:&
EXCLUSIVE: Longeveron's Lomecel-B Data In Alzheimer's Disease Published In Medical Journal
Longeveron Inc (NASDAQ: LGVN) announced the publication of Phase 1 trial results of Lomecel-B on patients with mild Alzheimer's disease (AD) in the Alzheimer's & Dementia journal.
Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab
In the partnership that spawned aducanumab, Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) have 
Prothena Highlinghts New Preclinical Data For Alzheimer's, Parkinson's Vaccine Programs
Prothena Corporation plc (NASDAQ: PRTA) 
Gain Therapeutics Posts Encouraging Preclinical Data From Parkinson's, Alzheimer's Programs
Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact

Connect With Us

instagramlinkedinyoutube

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2025 Benzinga | All Rights Reserved